LEI: The Future of Medicine in Advanced TherapiesFri, 09/20/2019 - 10:28
The horizons of medicine are defined by the possibilities brought by new therapeutic resources to attack diseases that have yet to be treated successfully. Gene therapy, cell therapy, tissue engineering and their combinations are collectively known as advanced therapies.
Laboratorios de Especialidades Inmunológicas (LEI) provides its services as a third party authorized by COFEPRIS. Since 1991, LEI has held a distinctive catalog of the most innovative market research tools and solutions, driven by requests from its customers.
Advanced therapies have emerged to treat acute lymphoblastic leukemia in children with CART cells, including three-dimensional biological impressions to restore patient mobility. New opportunities, however, bring fresh difficulties. Entry to this market is restricted either by the absence of the definition of health regulation or by ignorance and insufficient interpretation of regulations, which can jeopardize the effect of sophisticated therapies on patients.
LEI helps its clients navigate sanitary regulation. Its technological management model, supported by consolidated tools for the development and quality control of advanced therapies, resulted in LEI winning the 2018 National Prize for Technology and Innovation. With state-of-the-art infrastructure and a mature quality-management system, LEI meets international performance standards, leading its customers through the path of local and global health regulation.